ECR 2013

Mar 10, 2013

Samsung is highlighting its BodyTom portable CT scanner for the first time since the company acquired its developer, NeuroLogica, in January 2013.

none
Latest in Conference
Modern glass and steel building with blue mobile information booth and visitors in courtyard under clear blue sky
Rapid-fire research showcases neuroradiology innovations
November 2, 2026
Professional headshot of a man with dark hair and facial hair against a white background
EANM: How PET is reshaping Alzheimer's treatment decisions
October 29, 2026
FREE webinar: find your imaging capacity
Sponsored
FREE webinar: find your imaging capacity
October 22, 2026
Research presentation on nuclear medicine fragmentation showing 25 studies with PET imaging criteria analysis and expert interview
EANM: Is ‘research fragmentation’ holding back nuclear medicine?
October 21, 2026
Related Stories
2013 03 11 14 43 21 277 2013 03 11 Von Schulthess 70
Conference
'Unfair' regulatory stance on radiotracers poses threat to PET's future
2013 03 11 13 41 58 776 2013 03 11 De Jonge 175 20130311205113
Conference
Gymnasts' spines, footballers' ankles, and golfers' wrists take the strain
2013 03 11 13 05 10 976 2013 03 11 Panel 20130311201135
Conference
A 3-piece jigsaw: patient, radiologist, clinician. But do they fit together?
FREE webinar: find your imaging capacity
Sponsor Content
FREE webinar: find your imaging capacity
More in Conference
Rapid-fire research showcases neuroradiology innovations
By Claudia Tschabuschnig
Scientific findings in just a few minutes: The PowerPitches format brought together a fast-paced selection of emerging research across neuroradiology.
November 2, 2026
Modern glass and steel building with blue mobile information booth and visitors in courtyard under clear blue sky
EANM: How PET is reshaping Alzheimer's treatment decisions
By Claudia Tschabuschnig
As disease-modifying therapies enter clinical practice, amyloid and tau PET are taking on increasingly important roles in patient selection, disease staging, and treatment monitoring.
October 29, 2026
Professional headshot of a man with dark hair and facial hair against a white background
neuroRAD 2026: What the EU AI Act means for clinical neuroradiology
By Claudia Tschabuschnig
At neuroRAD 2026 in Mainz, Dr. Joel Kohler of Heidelberg University Hospital discussed how the EU AI Act could affect clinical neuroradiology.
October 26, 2026
Smiling man in dark sweater with cream collar standing in modern office with large windows overlooking green landscape
EANM: Is ‘research fragmentation’ holding back nuclear medicine?
By Will Morton
Well-designed studies require collaboration among nuclear medicine, medical oncology, urology, radiation oncology, and clinical trial support.
October 21, 2026
Research presentation on nuclear medicine fragmentation showing 25 studies with PET imaging criteria analysis and expert interview
Video from EANM: Wadsak discusses new radiopharmaceutical targets and supply challenges
By Claudia Tschabuschnig
At EANM Prof. Wolfgang Wadsak sees both scientific opportunities and practical obstacles ahead for radiopharmaceutical development.
October 21, 2026
Professional man in light blue blazer speaking at conference with microphone and lanyard badge
EANM 2026 Photo Gallery
By Claudia Tschabuschnig
We present our collection of images from EANM 2026. This gallery is updated daily during the congress.
October 21, 2026
EIA26 Vienna conference venue with blue overhead displays welcoming attendees and orange 'VILLAGE' signage at the entrance
EANM: AI studies target tumor boards, PET/CT protocoling, and PD-L1 prediction
By Claudia Tschabuschnig
A multi-agent AI system improved tumor board recommendations, while other studies explored PET/CT protocol selection and cancer biomarker prediction at EANM 2026 in Vienna.
October 20, 2026
Conference hall with attendees seated facing a large blue projection screen displaying Vienna event branding and architectural imagery
EANM: Lu-177 edotreotide dose linked to tumor response
By AuntMinnieEurope.com staff writers
Objective response rates climbed from 12% in the lowest dose quartile to 64% in the highest.
October 20, 2026
A26 NMM World Leading Meeting event branding displayed over an aerial cityscape at sunset
EANM: New PET tracer shows promise in kidney cancer
By Will Morton
Across 492 true lesions evaluated in the study, Ga-68 DPI-4452 PET/CT detected 90.9%, compared with 56.7% using F-18 FDG PET/CT.
October 20, 2026
A26 NMM World Leading Meeting event branding overlay on aerial city skyline at sunset
EANM 2026 opened with Nobel lessons and waltz
By Claudia Tschabuschnig
The opening ceremony of EANM 2026 combined scientific inspiration with a Viennese waltz.
October 19, 2026
Formal event on stage with elegantly dressed guests and musicians performing on large screen display above
Video from EANM: President Erba on radiopharmaceuticals, PET, and AI
By Claudia Tschabuschnig
Advances in radiopharmaceuticals, PET imaging, and AI are driving personalized nuclear medicine, according to EANM President Prof. Paola Anna Erba.
October 19, 2026
Woman wearing glasses and gray blazer speaking at a microphone during a professional conference or event
EANM 2026: How early is early enough in prevention?
By Claudia Tschabuschnig
Experts question whether PET-based screening is ready for cancer, heart disease, and Alzheimer’s, and what evidence would justify it.
October 19, 2026
Panel discussion at ISTAT26 conference in Vienna with speaker presenting on stage while seated panelists listen
Page 1 of 148
Next Page